menu

Incorporating Scientific Advances into Myelofibrosis Treatment Plans

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Incorporating Scientific Advances into Myelofibrosis Treatment Plans

5 chapters
Play All
1.00 credits
60 min
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    MF is a BCR-ABL1–negative chronic myeloproliferative neoplasm (MPN), a collection of heterogeneous cancers that includes primary MF (PMF) and secondary MF that sometimes forms in patients first diagnosed with polycythemia vera (PV) or essential thrombocythemia (ET). The role of the JAK pathway and its aberrant activation in MF has long been appreciated. Importantly, the treatment armamentarium for MF is expanding with the emergence of new agents targeting the JAK pathway alongside other key regulators of immunity and inflammation. As such, treatment selection for MF is increasingly based on patient preference, with consideration given to treatment-related side effects, symptom burden, and transfusion dependency.

    This educational initiative will update the interprofessional care team on current and emerging therapies for the treatment and management of MF, including treatment risks and benefits, barriers to adherence, and side effect monitoring and management. These concepts are coupled with education about shared decision-making strategies and other related approaches to achieve increased patient satisfaction, better adherence to treatment plans, and greater treatment engagement, as well as to enhance quality decision-making.

    FDA Approval September 2023: Momelotinib as First- and Second-line Treatment

    For the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia), in adults with anemia.

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty, Ruben A. Mesa, MD, FACP reported a financial interest/relationship or affiliation in the form of Contracted research: Bristol-Myers Squibb Company, CTI BioPharma Corporation, Imago, Incyte Corporation, Ionis, Morphosys, Pharmessentia. Consultant: CTI BioPharma Corporation, Geron, Incyte Corporation, Novartis Pharmaceuticals Corporation, Protagonist, Sierra, Telios.

     

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS;Stephanie Wenick, MPhil; Joseph Kim, MD, MPH, MBA; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP, hereby state that they do not have any financial relationships or relationships with any ineligible company of any amount during the past 24 months. 

  • Target Audience

    This initiative is designed for hematologists, oncologists, physician assistants, nurse practitioners, pharmacists, and other healthcare practitioners who are part of the care team that treat or manage patients with MF.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Summarize MF disease burden and impact on patients’ quality of life (QoL)
    2. Apply guideline-recommended, evidence-based, prognostic, and risk-stratification approaches in clinical practice 
    3. Evaluate clinical safety, efficacy, and tolerability/durability data for approved and emerging therapeutic agents/combinations, including data pertaining to improving QoL and reducing symptom burden (anemia and transfusion dependency)
    4. Develop personalized care and treatment plans that incorporate disease- and patient-specific factors
  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Q Synthesis LLC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

     Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

     

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until July 20th, 2024. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists

    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-9999-23-019-H01-P.

    Credit Designation for Nursing

    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

     Laboratory Professionals

    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credits. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

     

     

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Jointly provided by  

  • Commercial Support

    This educational activity is supported by educational grants from GSK, Incyte Corporation, CTI BioPharma Corporation, and Bristol Myers Squibb Company.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    MF is a BCR-ABL1–negative chronic myeloproliferative neoplasm (MPN), a collection of heterogeneous cancers that includes primary MF (PMF) and secondary MF that sometimes forms in patients first diagnosed with polycythemia vera (PV) or essential thrombocythemia (ET). The role of the JAK pathway and its aberrant activation in MF has long been appreciated. Importantly, the treatment armamentarium for MF is expanding with the emergence of new agents targeting the JAK pathway alongside other key regulators of immunity and inflammation. As such, treatment selection for MF is increasingly based on patient preference, with consideration given to treatment-related side effects, symptom burden, and transfusion dependency.

    This educational initiative will update the interprofessional care team on current and emerging therapies for the treatment and management of MF, including treatment risks and benefits, barriers to adherence, and side effect monitoring and management. These concepts are coupled with education about shared decision-making strategies and other related approaches to achieve increased patient satisfaction, better adherence to treatment plans, and greater treatment engagement, as well as to enhance quality decision-making.

    FDA Approval September 2023: Momelotinib as First- and Second-line Treatment

    For the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia), in adults with anemia.

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty, Ruben A. Mesa, MD, FACP reported a financial interest/relationship or affiliation in the form of Contracted research: Bristol-Myers Squibb Company, CTI BioPharma Corporation, Imago, Incyte Corporation, Ionis, Morphosys, Pharmessentia. Consultant: CTI BioPharma Corporation, Geron, Incyte Corporation, Novartis Pharmaceuticals Corporation, Protagonist, Sierra, Telios.

     

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS;Stephanie Wenick, MPhil; Joseph Kim, MD, MPH, MBA; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP, hereby state that they do not have any financial relationships or relationships with any ineligible company of any amount during the past 24 months. 

  • Target Audience

    This initiative is designed for hematologists, oncologists, physician assistants, nurse practitioners, pharmacists, and other healthcare practitioners who are part of the care team that treat or manage patients with MF.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Summarize MF disease burden and impact on patients’ quality of life (QoL)
    2. Apply guideline-recommended, evidence-based, prognostic, and risk-stratification approaches in clinical practice 
    3. Evaluate clinical safety, efficacy, and tolerability/durability data for approved and emerging therapeutic agents/combinations, including data pertaining to improving QoL and reducing symptom burden (anemia and transfusion dependency)
    4. Develop personalized care and treatment plans that incorporate disease- and patient-specific factors
  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Q Synthesis LLC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

     Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

     

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until July 20th, 2024. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists

    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-9999-23-019-H01-P.

    Credit Designation for Nursing

    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

     Laboratory Professionals

    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credits. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

     

     

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Jointly provided by  

  • Commercial Support

    This educational activity is supported by educational grants from GSK, Incyte Corporation, CTI BioPharma Corporation, and Bristol Myers Squibb Company.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

loader-imageLoading...
Schedule3 Mar 2024